



FOR IMMEDIATE RELEASE

Invitrocue Announces Merger with Angsana Molecular & Diagnostics Laboratory and Pathnova Laboratories to Build a Leading Integrated Cancer Diagnostics Platform

Singapore — [8th April 2026] — Invitrocue today announced a strategic merger with Angsana Molecular & Diagnostics Laboratory Pte. Ltd. and Pathnova Laboratories Pte. Ltd., marking a significant step in the Group’s expansion and market coverage strategy. Angsana and Pathnova were companies under the Archerfish Precision Diagnostics group previously. Both Angsana and Pathnova will operate as wholly-owned subsidiaries under Invitrocue, which will serve as the holding company of the enlarged group.

This consolidation brings together three complementary diagnostic platforms into a unified, scaled business designed to meet the growing demand for high-quality, integrated diagnostic services in Singapore, across the Asia-Pacific region and Europe. By combining their respective strengths, the enlarged Invitrocue Group is positioned to deliver a broader range of Personalised Cancer Diagnostic services, enhanced operational efficiency, and a stronger value proposition to healthcare providers and institutional partners. The Group now offers next generation clinical Cancer Organoid based approaches in drug selection and advanced Liquid Biopsy for early cancer detection, cancer treatment monitoring and relapse monitoring.

The merger will unlock immediate and tangible synergies across both revenue generation and clinical adoption. With an expanded client base spanning hospitals, clinicians, and healthcare institutions, the Group will be able to cross-sell a wider suite of diagnostic services and introduce more integrated, bundled solutions. This is anticipated to drive stronger client retention, increase wallet share, and accelerate revenue growth.

Operationally, the integration will enable the consolidation of laboratory infrastructure, streamlining of workflows, and optimisation of procurement and shared services. These initiatives are expected to improve efficiency, enhance scalability, and support higher



testing volumes, strengthening the Group's ability to deliver consistent, high-quality services.

Strategically, the enlarged platform reinforces Invitrocue's position as a key player in Personalised Cancer diagnostics sector and establishes a solid foundation for regional expansion. With increased scale and capabilities, the Group will be better positioned to pursue new partnerships, enter additional markets, and execute targeted acquisitions to further drive growth.

Commenting on the transaction, Mr. Kevin Lee, CEO, Angsana said: "Asia remains our core hub, and from here we intend to expand our footprint globally with a strong, execution-driven strategy." Dr. Chung Jinhyuk, Chief Scientific Officer, Invitrocue Group, added and said: "By merging Angsana and Pathnova into Invitrocue, we are creating Best-in-Class & First-in-Class powerhouse for personalized oncology. This integration allows us to expedite the delivery of our world's best-performing cancer liquid biopsy and treatment guidance solutions to clinics across the region and beyond, driving superior patient outcomes globally and escalating our shareholder values."

The transaction reflects Invitrocue's continued focus on building a high-quality, scalable cancer diagnostics platform with recurring revenue characteristics and strong operational leverage. The Group believes this positions it well to capture the increasing demand for advanced diagnostic services and to deliver sustainable long-term value for shareholders.

For further information and inquiry, please contact:

INVITROCUE

Dr. Steven Fang
CEO, Invitrocue Ltd
M: +65 6460 0497
E: steven.fang@invitrocue.com
Website : <https://invitrocue.com>

ANGSANA MOLECULAR & DIAGNOSTICS LABORATORY

Mr. Kevin Lee
CEO, Angsana Molecular & Diagnostics Laboratory Pte Ltd
T: +65 6421 3868
kevin.lee@angsanalabs.com
Website: <https://angsanalabs.com>